Learning Objectives:
1. Describe basal ganglia dysfunction and target selection to treat Parkinson’s disease and essential tremor with MRgFUS
2. Discuss the clinical outcomes and indications of MRgFUS in Parkinson’s disease and essential tremor and ongoing trials for other movement disorders with high intensity FUS
3. Describe the physical principles of BBB, the ongoing studies on opening the BBB as a therapeutic strategy and a method for drug delivery and their potential use in clinical setting